You are here

Article info

Article menu

Download PDFPDF

Case Report
A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab

Authors

  • Jaqueline Ghosn Department of Medicine, Division of Immunology and AllergyLausanne University Hospital CHUV Rue du Bugnon 46 CH-1011 Lausanne Switzerland PubMed articlesGoogle scholar articles
  • Alex Vicino Department of NeurologyLausanne University Hospital CHUV Rue du Bugnon 46 CH-1011 Lausanne Switzerland PubMed articlesGoogle scholar articles
  • Olivier Michielin Department of Medical OncologyLausanne University Hospital CHUV Rue du Bugnon 46 CH-1011 Lausanne Switzerland PubMed articlesGoogle scholar articles
  • George Coukos Department of Medical OncologyLausanne University Hospital CHUV Rue du Bugnon 46 CH-1011 Lausanne Switzerland Ludwig Institute for Cancer Research Chemin des Boveresses 155 CH-1066 Epalinges Switzerland PubMed articlesGoogle scholar articles
  • Thierry Kuntzer Department of NeurologyLausanne University Hospital CHUV Rue du Bugnon 46 CH-1011 Lausanne Switzerland PubMed articlesGoogle scholar articles
  • Michel Obeid Department of Medicine, Division of Immunology and AllergyLausanne University Hospital CHUV Rue du Bugnon 46 CH-1011 Lausanne Switzerland Vaccination and Immunotherapy CenterLausanne University Hospital CHUV Rue du Bugnon 17 CH-1011 Lausanne Switzerland Medical School Pitié-SalpêtrièreSorbonne University 91 Boulevard de l’Hôpital F-75013 Paris France PubMed articlesGoogle scholar articles
  1. ↵f michel.obeid{at}chuv.ch
View Full Text

Citation

Ghosn J, Vicino A, Michielin O, et al
A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab
Journal for ImmunoTherapy of Cancer 2018;6:110. doi: 10.1186/s40425-018-0429-4

Publication history

  • Received July 13, 2018
  • Accepted October 11, 2018
  • First published October 22, 2018.
Online issue publication 
February 10, 2021

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.